IPO Year: 2014
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $5.00 | Overweight → Equal Weight | Barclays |
| 10/14/2025 | Outperform → Mkt Perform | Raymond James | |
| 10/13/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 10/13/2025 | $78.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 10/13/2025 | $61.00 | Overweight | Barclays |
| 7/14/2025 | $62.00 | Outperform | Raymond James |
| 7/11/2025 | $52.00 | Overweight | Cantor Fitzgerald |
| 6/12/2025 | $78.00 | Overweight | Piper Sandler |
| 5/21/2025 | $65.00 | Outperform | Oppenheimer |
| 5/15/2025 | $55.00 | Buy | BTIG Research |
Fastest customizable press release news feed in the world
HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th – 15th, 2026, in San Francisco, CA. During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmona
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109, on track for H1 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). Preliminary results were announced on
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company's management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY. Details are as follows: Piper Sandler 37th Annual Healthcare Conference Format: Fireside Chat Date: Tuesday, December 2, 2025 Time: 12:00 PM ET The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the w
On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 Results from healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, expected in H1 2026 Cash runway sufficient to fund operations into Q4 2026 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, November 18, 2025, at 9:30 AM GMT. Management will also host investor one-on-one meetings throughout the conference. The Jefferies Global Healthcare Conference 2025 is taking place November 17-20, 2025 in London, UK. This year's gathering marks the 16th anniversary of the largest healthcare-dedicated conference in Europe and will bring together leadin
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company
On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway anticipated to be sufficient to fund operations into Q4 2026 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for patients with idiopathic
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 60 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company fo
Topline data from the REVERT IPF trial anticipated in 4Q 2025 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3.
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
S-8 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
S-1/A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
S-1/A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays downgraded Tvardi Therapeutics from Overweight to Equal Weight and set a new price target of $5.00
Raymond James downgraded Tvardi Therapeutics from Outperform to Mkt Perform
Cantor Fitzgerald downgraded Tvardi Therapeutics from Overweight to Neutral
Piper Sandler downgraded Tvardi Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $78.00 previously
Barclays initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $61.00
Raymond James initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $62.00
Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $52.00
Piper Sandler initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $78.00
Oppenheimer initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $65.00
BTIG Research initiated coverage of Tvardi Therapeutics with a rating of Buy and set a new price target of $55.00
Live finance-specific insights
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory